Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of cabazitaxel in recurrent or metastatic head and neck cancer after failure of cisplatin, cetuximab and taxanes
2011-004712-32Phase 2Completed
- Sponsor
- Unicancer
- Start
- Dec 2011
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel in head and neck cancer (HNC), sponsored by Unicancer. Primary endpoint: Non-progression at 6 weeks. Started Dec 2011; status: completed.
02
Drugs
cabazitaxel
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on 2011-004712-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004712-32.